1. Home
  2. GMAB

GMAB

Genmab A/S ADS

Logo Genmab A/S ADS

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Founded: 1999 Country:
Denmark
Denmark
Employees: N/A City: N/A
Market Cap: 19.1B IPO Year: N/A
Target Price: $45.20 AVG Volume (30 days): 579.9K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.94 EPS Growth: -20.05
52 Week Low/High: $26.32 - $43.00 Next Earning Date: 05-08-2024
Revenue: $2,440,592,593 Revenue Growth: 13.57%
Revenue Growth (this year): 15.13% Revenue Growth (next year): 20.28%

Share on Social Networks: